Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 15/20 | 0.79 |
| ▸ | MMEL1 | Q495T6 | 7/20 | 0.69 |
| ▸ | ACE | P12821 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2707568 | 1.00 | MME (0.79) | MMEMMEL1ACE | |
| SCHEMBL18672723 | 1.00 | MME (0.79) | MMEMMEL1ACE | |
| SCHEMBL2707363 | 0.90 | MME (0.66) | MMEMMEL1ACE | |
| SCHEMBL3699445 | 0.89 | MME (1.00) | MMEMMEL1ACE | |
| SCHEMBL1912523 | 0.88 | MMEL1 (0.68) | MMEMMEL1ACE | |
| SCHEMBL1912518 | 0.88 | MMEL1 (0.68) | MMEMMEL1ACE | |
| SCHEMBL18672772 | 0.87 | MME (0.82) | MMEMMEL1ACE | |
| SCHEMBL2705863 | 0.83 | MME (0.73) | MMEMMEL1ACE | |
| SCHEMBL2705954 | 0.83 | MME (0.73) | MMEMMEL1ACE | |
| SCHEMBL1912661 | 0.83 | MMEL1 (0.62) | MMEMMEL1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9603819-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, GABRB1, GABRE | MME 1/4885MMEL1 427/4885ACE 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.